Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly

Drugs Aging. 1997 Dec;11(6):470-9. doi: 10.2165/00002512-199711060-00006.

Abstract

Nifedipine, the prototype for the dihydropyridine class of calcium antagonists, has been available for 20 years and its efficacy as a vasodilator and an antihypertensive agent is well recognised. The development of the so-called nifedipine gastrointestinal therapeutic system (GITS), which allows once-daily administration, has modified and improved the overall therapeutic profile of nifedipine to such a significant extent that it might almost be considered a new drug entity. The nifedipine GITS is associated with distinct improvements in terms of patient compliance and convenience, and a reduced incidence of adverse effects. With regard to the care of the elderly, this 'new' drug offers the prospect of a well tolerated and effective treatment without major cost implications.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Aged
  • Aging / blood*
  • Calcium Channel Blockers / pharmacokinetics*
  • Cost-Benefit Analysis
  • Delayed-Action Preparations
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems
  • Humans
  • Nifedipine / economics
  • Nifedipine / pharmacokinetics*
  • Nifedipine / pharmacology
  • Patient Compliance
  • Vasodilator Agents / pharmacokinetics*

Substances

  • Calcium Channel Blockers
  • Delayed-Action Preparations
  • Vasodilator Agents
  • Nifedipine